{
    "clinical_study": {
        "@rank": "89199", 
        "arm_group": [
            {
                "arm_group_label": "FEC", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients will be randomized to received 4 cycles of fluorouracil, epirubicin and cyclophosphamide before surgery, and 4 cycles of docetaxel after surgery."
            }, 
            {
                "arm_group_label": "XEC", 
                "arm_group_type": "Experimental", 
                "description": "Patients will be randomized to received 4 cycles of capecitabine, epirubicin and cyclophosphamide before surgery, and 4 cycles of docetaxel and capecitabine after surgery."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized phase II trial compared pathologic response rates (pCR) of early breast\n      cancer following neoadjuvant fluorouracil-epirubicin-cyclophosphamide(FEC) and\n      capecitabine-epirubicin-cyclophosphamide (XEC)."
        }, 
        "brief_title": "Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer", 
        "condition": [
            "Stage II Breast Cancer", 
            "Stage III Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Females aged 18-70 with histologically proven, core-biopsied, Stage II-III invasive\n             breast cancer\n\n          -  No distant disease\n\n        Exclusion Criteria:\n\n        - Inadequate heart or liver or kidney function"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02115152", 
            "org_study_id": "JLiu"
        }, 
        "intervention": [
            {
                "arm_group_label": "FEC", 
                "intervention_name": "fluorouracil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "XEC", 
                "intervention_name": "capecitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "FEC", 
                    "XEC"
                ], 
                "intervention_name": "cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "FEC", 
                    "XEC"
                ], 
                "intervention_name": "Epirubicin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Fluorouracil", 
                "Capecitabine", 
                "Epirubicin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Capecitabine", 
            "Neoadjuvant therapy", 
            "Early Breast Cancer"
        ], 
        "lastchanged_date": "April 14, 2014", 
        "location": {
            "contact": {
                "last_name": "Jianlun Liu, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Nanning", 
                    "country": "China", 
                    "state": "Guangxi"
                }, 
                "name": "Breast Cancer Surgery Department of Guangxi Medical University Cancer Center"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Neoadjuvant Trial of Capecitabine, Cyclophosphamide and Epirubicin for Patients With Axillary Lymph Node Positive Stage II-III Operable Breast Cancer", 
        "overall_contact": {
            "email": "jianlunliu@hotmail.com", 
            "last_name": "Jianlun Liu"
        }, 
        "overall_official": {
            "affiliation": "Guangxi Medical University Cancer Center", 
            "last_name": "Jianlun Liu, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The absence of invasive tumor in the final surgical breast sample (stage yT0 or ypTis)", 
            "measure": "pathologic response rates (pCR)", 
            "safety_issue": "No", 
            "time_frame": "The breast sample will be evaluaed on the day of surgery during the cycle 4, an expected average of 12 weeks."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02115152"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Guangxi Medical University", 
            "investigator_full_name": "Jianlun Liu", 
            "investigator_title": "Director of Department of Breast Surgery", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Time from randmization to breast-cancer recurrence, or a second primay cancer(ecluding contralateral ducal carcinoma in situ), or death from any cause, whichever comes first", 
                "measure": "DFS(Disease free survial)", 
                "safety_issue": "No", 
                "time_frame": "Participants will be evaluated on Day 1 of each cycle during chemotherapy, and Day 1 every 3 months after completion of chemotherapy. The expected average of 5 years."
            }, 
            {
                "description": "Adverse events are classified accoding  NCI CTC criteria.", 
                "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Hematologic, renal, and hepatic funcion will be assessed after each cycle and at the end of therapy, an expected average of 3 weeks."
            }
        ], 
        "source": "Guangxi Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Guangxi Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}